CAR T Cells Targeting FLT3 on AML Confer Potent Anti-Leukemic Activity and Act Synergistically with the FLT3 Inhibitor Midostaurin

被引：0
|
作者：
Jetani, Hardikkumar
Garcia-Cadenas, Irene
Nerreter, Thomas
Rydzek, Julian
Thomas, Simone
Herr, Wolfgang
Sierra, Jordi
Bonig, Halvard
Einsele, Hermann
Hudecek, Michael
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1351
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
    Hardikkumar Jetani
    Irene Garcia-Cadenas
    Thomas Nerreter
    Simone Thomas
    Julian Rydzek
    Javier Briones Meijide
    Halvard Bonig
    Wolfgang Herr
    Jordi Sierra
    Hermann Einsele
    Michael Hudecek
    Leukemia, 2018, 32 : 1168 - 1179
  • [2] CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
    Jetani, Hardikkumar
    Garcia-Cadenas, Irene
    Nerreter, Thomas
    Thomas, Simone
    Rydzek, Julian
    Briones Meijide, Javier
    Bonig, Halvard
    Herr, Wolfgang
    Sierra, Jordi
    Einsele, Hermann
    Hudecek, Michael
    LEUKEMIA, 2018, 32 (05) : 1168 - 1179
  • [3] FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells
    Jetani, Hardikkumar
    Garcia-Cadenas, Irene
    Nerreter, Thomas
    Goetz, Ralph
    Sierra, Jorge
    Bonig, Halvard
    Sauer, Markus
    Einsele, Hermann
    Hudecek, Michael
    BLOOD, 2018, 132
  • [4] Plm-102, a Next Generation FLT3 Inhibitor, Shows Potent Anti-Leukemic Activity on Resistance to Gilteritinib in FLT3 Mutated Acute Myeloid Leukemia
    Lee, Jae-Seon
    Park, Min Ji
    Sun, Ningning
    Park, Jin-Hee
    Oh, Su-jin
    Moon, Miran
    Kim, Myung Jin
    Jang, Soo Yeon
    Kim, Yong-Chul
    BLOOD, 2023, 142
  • [5] Gilteritinib: potent targeting of FLT3 mutations in AML
    Levis, Mark
    Perl, Alexander E.
    BLOOD ADVANCES, 2020, 4 (06) : 1178 - 1191
  • [6] Evaluation of a FLT3 inhibitor as an anti-leukemic agent for acute myeloid leukemia
    Jeong, Pyeonghwa
    Lee, Jungeun
    Lee, Hyo Jeong
    Baek, Juhwa
    Choi, Jungil
    Chin, Young-Won
    Choi, Young Hee
    Kim, Yong-Chul
    Han, Sun-Young
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [7] Targeting of SFK and G6PD Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations
    Koralkova, Pavla
    Niederlova, Nikola
    Hradilova, Iveta
    Gursky, Jan
    Cudova, Barbora
    Urbankova, Helena
    Reznickova, Eva
    Gucky, Tomas
    Myslivcova, Denisa
    Belickova, Monika
    Krystof, Vladimir
    Divoky, Vladimir
    BLOOD, 2022, 140 : 8823 - 8824
  • [8] Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells
    Drexler, HG
    LEUKEMIA, 1996, 10 (04) : 588 - 599
  • [9] Bone Marrow Stromal Cells Protect Both FLT3-ITD and FLT3-WT Primary AML Cells from the Anti-Leukemic Activity of the FLT3 Inhibitor AC220
    Dos Santos, Cedric
    Ndikuyeze, Georges Habineza
    Nisssan, Michael
    Zhou, Chenghui
    Shan, Xiaochuan
    Perl, Alexander E.
    Carroll, Martin P.
    Danet-Desnoyers, Gwenn
    BLOOD, 2014, 124 (21)
  • [10] Factors Predicting Response and Resistance to Midostaurin in FLT3 Positive and FLT3 Negative AML in 483 Primary AML Patient Samples
    Watanabe-Smith, Kevin
    Rosenberg, Mara
    Bucy, Taylor
    Tyner, Jeffrey W.
    Borate, Uma
    BLOOD, 2017, 130
12345